Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057. Lilly is launching a tender offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback